Vanderbilt University researcher William Mitchell, M.D., Ph.D., and colleagues in Germany and Canada have demonstrated a method for detecting “cell-free” tumor DNA in the bloodstream. Mitchell believes the technique will be transformative in provid ...
A team of researchers led by Duke Cancer Institute has identified key events that prompt certain cancer cells to develop cancer drug resistance to otherwise lethal therapies. By mapping the specific steps that cells of melanoma, breast cancer, and a ...
An experimental cancer drug may block an important driver for the survival, growth and spread of cancer cells. The first clinical trial of an experimental drug, called pictilisib, found the safety profile to be manageable in cancer patients at dose ...
Johns Hopkins researchers have developed a sugar-based molecular microcapsule that eliminates the toxicity of an anticancer agent developed a decade ago at Johns Hopkins, called 3-bromopyruvate, or 3BrPA, in studies of mice with implants of human pan ...
Results of a Phase 2, open-label, dose-confirmation study of eribulin in combination with capecitabine, suggests that this therapy is efficacious in women with metastatic breast cancer (overall response rate 42.9% and clinical benefit rate 57.1%), wi ...
Doctors and scientists from The University of Manchester have identified changes in a gene, which can increase the risk of developing brain tumors in children with a rare inherited condition called Gorlin syndrome. Gorlin syndrome causes an increase ...
Although prostate cancer can be successfully treated in many men, when the disease develops bone metastases, it is eventually lethal. In a study published online in the journal Cancer Research, researchers show that the receptor CCR5, best known for ...
University of Technology Sydney (UTS) research crunching vast amounts of data on childhood cancer to better tailor treatment is one step closer to assisting clinicians as the collaboration with the Kids Research Institute at The Children's Hospital a ...
Scientists at the University of Manchester have discovered a potential weakness in cancer’s ability to return or become resistant to treatment, by targeting the ‘fuel’ part of stem cells which allows tumors to grow. Cancer stem cells are particularl ...
The results from a pooled analysis of two Phase 3 Halaven (eribulin) trials are published in Breast Cancer Research and Treatment. Findings from the pooled analysis show that eribulin improves overall survival in women compared to control. This overa ...